Kosin Med J.  2024 Mar;39(1):18-25. 10.7180/kmj.24.107.

Exploring the nexus between obesity, metabolic syndrome, and colorectal cancer

• Lee JY

• KMID: 2556794
• DOI: http://doi.org/10.7180/kmj.24.107

Abstract

The increasing global prevalence of obesity and metabolic syndrome (MetS) is strongly associated with the incidence of colorectal cancer (CRC). Obesity and MetS detrimentally impact the treatment outcomes of CRC and share similar mechanisms that contribute to the development of CRC. Increased insulin resistance in patients with obesity is linked to CRC, and altered levels of sex hormones and adipokines affect cell growth and inflammation. Obesity and MetS also alter the gut microbiome. Bile acids, which are crucial for lipid metabolism, are elevated in patients with obesity. Moreover, specific bile acids are associated with colonic damage, inflammation, and the development of CRC. Obesity and MetS increase the risk of postoperative complications and affect the response to chemotherapy. The promotion of weight loss and the resolution of MetS can reduce the occurrence of CRC and increase treatment efficacy. Therefore, it is imperative to implement appropriate management strategies to address obesity and MetS with the aim of improving the prognosis and reducing the incidence of CRC. Moreover, additional research should be conducted to determine the optimal timing for tailored CRC screening in patients with obesity or MetS. In this review, we explore the impact of obesity and MetS on the development of CRC and examine potential strategies to mitigate CRC risk in individuals with obesity and MetS.

Keyword

Colorectal neoplasms; Metabolic syndrome; Obesity

Reference

References

1. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023; 73:17–48.

2. Jasperson KW, Tuohy TM, Neklason DW, Burt RW. Hereditary and familial colon cancer. Gastroenterology. 2010; 138:2044–58.

3. Sung H, Siegel RL, Torre LA, Pearson-Stuttard J, Islami F, Fedewa SA, et al. Global patterns in excess body weight and the associated cancer burden. CA Cancer J Clin. 2019; 69:88–112.

4. Flegal KM, Kruszon-Moran D, Carroll MD, Fryar CD, Ogden CL. Trends in obesity among adults in the United States, 2005 to 2014. JAMA. 2016; 315:2284–91.

5. Shin A, Jung KW, Jeong SY. Right then, wrong now: early-onset colorectal cancer in Korea. Cancer Res Treat. 2023; 55:1058–60.

6. Aguilar M, Bhuket T, Torres S, Liu B, Wong RJ. Prevalence of the metabolic syndrome in the United States, 2003-2012. JAMA. 2015; 313:1973–4.

7. Lim S, Shin H, Song JH, Kwak SH, Kang SM, Won Yoon J, et al. Increasing prevalence of metabolic syndrome in Korea: the Korean National Health and Nutrition Examination Survey for 1998-2007. Diabetes Care. 2011; 34:1323–8.

8. Tran BT, Jeong BY, Oh JK. The prevalence trend of metabolic syndrome and its components and risk factors in Korean adults: results from the Korean National Health and Nutrition Examination Survey 2008-2013. BMC Public Health. 2017; 17:71.

9. Lee CG, Lee JK, Kang YS, Shin S, Kim JH, Lim YJ, et al. Visceral abdominal obesity is associated with an increased risk of irritable bowel syndrome. Am J Gastroenterol. 2015; 110:310–9.

10. Chang P, Friedenberg F. Obesity and GERD. Gastroenterol Clin North Am. 2014; 43:161–73.

11. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006; 444:881–7.

12. Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K, et al. Body fatness and cancer: viewpoint of the IARC Working Group. N Engl J Med. 2016; 375:794–8.

13. Stefan N, Kantartzis K, Machann J, Schick F, Thamer C, Rittig K, et al. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med. 2008; 168:1609–16.

14. Wildman RP, Muntner P, Reynolds K, McGinn AP, Rajpathak S, Wylie-Rosett J, et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). Arch Intern Med. 2008; 168:1617–24.

15. Giovannucci E. Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. Am J Clin Nutr. 2007; 86:836S–842S.

16. Ning Y, Wang L, Giovannucci EL. A quantitative analysis of body mass index and colorectal cancer: findings from 56 observational studies. Obes Rev. 2010; 11:19–30.

17. Abar L, Vieira AR, Aune D, Sobiecki JG, Vingeliene S, Polemiti E, et al. Height and body fatness and colorectal cancer risk: an update of the WCRF-AICR systematic review of published prospective studies. Eur J Nutr. 2018; 57:1701–20.

18. Gathirua-Mwangi WG, Monahan P, Song Y, Zollinger TW, Champion VL, Stump TE, et al. Changes in adult BMI and waist circumference are associated with increased risk of advanced colorectal neoplasia. Dig Dis Sci. 2017; 62:3177–85.

19. Ma Y, Yang Y, Wang F, Zhang P, Shi C, Zou Y, et al. Obesity and risk of colorectal cancer: a systematic review of prospective studies. PLoS One. 2013; 8:e53916.

20. Seo JY, Jin EH, Chung GE, Kim YS, Bae JH, Yim JY, et al. The risk of colorectal cancer according to obesity status at four-year intervals: a nationwide population-based cohort study. Sci Rep. 2023; 13:8928.

21. Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome: a new worldwide definition. Lancet. 2005; 366:1059–62.

22. Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care. 2012; 35:2402–11.

23. Lee J, Lee KS, Kim H, Jeong H, Choi MJ, Yoo HW, et al. The relationship between metabolic syndrome and the incidence of colorectal cancer. Environ Health Prev Med. 2020; 25:6.

24. Mili N, Paschou SA, Goulis DG, Dimopoulos MA, Lambrinoudaki I, Psaltopoulou T. Obesity, metabolic syndrome, and cancer: pathophysiological and therapeutic associations. Endocrine. 2021; 74:478–97.

25. Jin EH, Han K, Lee DH, Shin CM, Lim JH, Choi YJ, et al. Association between metabolic syndrome and the risk of colorectal cancer diagnosed before age 50 years according to tumor location. Gastroenterology. 2022; 163:637–48.

26. Liu PH, Wu K, Ng K, Zauber AG, Nguyen LH, Song M, et al. Association of obesity with risk of early-onset colorectal cancer among women. JAMA Oncol. 2019; 5:37–44.

27. Chen H, Zheng X, Zong X, Li Z, Li N, Hur J, et al. Metabolic syndrome, metabolic comorbid conditions and risk of early-onset colorectal cancer. Gut. 2021; 70:1147–54.

28. Kobayashi H, Gieniec KA, Lannagan TR, Wang T, Asai N, Mizutani Y, et al. The origin and contribution of cancer-associated fibroblasts in colorectal carcinogenesis. Gastroenterology. 2022; 162:890–906.

29. Kapoor D, Malkin CJ, Channer KS, Jones TH. Androgens, insulin resistance and vascular disease in men. Clin Endocrinol (Oxf). 2005; 63:239–50.

30. Harbs J, Rinaldi S, Gicquiau A, Keski-Rahkonen P, Mori N, Liu X, et al. Circulating sex hormone levels and colon cancer risk in men: a nested case-control study and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2022; 31:793–803.

31. Aleksandrova K, Schlesinger S, Fedirko V, Jenab M, Bueno-de-Mesquita B, Freisling H, et al. Metabolic mediators of the association between adult weight gain and colorectal cancer: data from the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Am J Epidemiol. 2017; 185:751–64.

32. Fujisawa T, Endo H, Tomimoto A, Sugiyama M, Takahashi H, Saito S, et al. Adiponectin suppresses colorectal carcinogenesis under the high-fat diet condition. Gut. 2008; 57:1531–8.

33. Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS. Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst. 2005; 97:1688–94.

34. Centuori SM, Gomes CJ, Trujillo J, Borg J, Brownlee J, Putnam CW, et al. Deoxycholic acid mediates non-canonical EGFR-MAPK activation through the induction of calcium signaling in colon cancer cells. Biochim Biophys Acta. 2016; 1861:663–70.

35. Nguyen TT, Ung TT, Kim NH, Jung YD. Role of bile acids in colon carcinogenesis. World J Clin Cases. 2018; 6:577–88.

36. Friedrich N, Thuesen B, Jorgensen T, Juul A, Spielhagen C, Wallaschofksi H, et al. The association between IGF-I and insulin resistance: a general population study in Danish adults. Diabetes Care. 2012; 35:768–73.

37. Bogazzi F, Ultimieri F, Raggi F, Russo D, Vanacore R, Guida C, et al. PPARgamma inhibits GH synthesis and secretion and increases apoptosis of pituitary GH-secreting adenomas. Eur J Endocrinol. 2004; 150:863–75.

38. Saldeen J, Welsh N. p38 MAPK inhibits JNK2 and mediates cytokine-activated iNOS induction and apoptosis independently of NF-KB translocation in insulin-producing cells. Eur Cytokine Netw. 2004; 15:47–52.

39. Liu LH, Zhou GF, Zhou JJ, Rao SX, Zeng MS. Impact of visceral adipose tissue on the accuracy of T-staging by CT in colon cancer. Eur J Radiol. 2021; 134:109400.

40. Zhou Y, Wu L, Li X, Wu X, Li B. Outcome of laparoscopic colorectal surgery in obese and nonobese patients: a meta-analysis. Surg Endosc. 2012; 26:783–9.

41. Amri R, Bordeianou LG, Sylla P, Berger DL. Obesity, outcomes and quality of care: body mass index increases the risk of wound-related complications in colon cancer surgery. Am J Surg. 2014; 207:17–23.

42. He J, He M, Tang JH, Wang XH. Anastomotic leak risk factors following colon cancer resection: a systematic review and meta-analysis. Langenbecks Arch Surg. 2023; 408:252.

43. Almasaudi AS, McSorley ST, Edwards CA, McMillan DC. The relationship between body mass index and short term postoperative outcomes in patients undergoing potentially curative surgery for colorectal cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2018; 121:68–73.

44. Reudink M, Slooter CD, Janssen L, Lieverse AG, Roumen RM, Slooter GD. Metabolic syndrome: associations with adverse outcome after colorectal surgery. A systematic review and meta-analysis. Ann Med Surg (Lond). 2021; 71:102997.

45. Artac M, Korkmaz L, Coskun HS, Dane F, Karabulut B, Karaagac M, et al. Bevacuzimab may be less effective in obese metastatic colorectal cancer patients. J Gastrointest Cancer. 2019; 50:214–20.

46. Miyamoto Y, Oki E, Emi Y, Tokunaga S, Shimokawa M, Ogata Y, et al. Low visceral fat content is a negative predictive marker for bevacizumab in metastatic colorectal cancer. Anticancer Res. 2018; 38:491–9.

47. Jaspan V, Lin K, Popov V. The impact of anthropometric parameters on colorectal cancer prognosis: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2021; 159:103232.

48. Lu B, Qian JM, Li JN. The metabolic syndrome and its components as prognostic factors in colorectal cancer: a meta-analysis and systematic review. J Gastroenterol Hepatol. 2023; 38:187–96.

49. Christakoudi S, Pagoni P, Ferrari P, Cross AJ, Tzoulaki I, Muller DC, et al. Weight change in middle adulthood and risk of cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Int J Cancer. 2021; 148:1637–51.

50. Luo J, Hendryx M, Manson JE, Figueiredo JC, LeBlanc ES, Barrington W, et al. Intentional weight loss and obesity-related cancer risk. JNCI Cancer Spectr. 2019; 3:pkz054.

51. Afshar S, Kelly SB, Seymour K, Lara J, Woodcock S, Mathers JC. The effects of bariatric surgery on colorectal cancer risk: systematic review and meta-analysis. Obes Surg. 2014; 24:1793–9.

52. Almazeedi S, El-Abd R, Al-Khamis A, Albatineh AN, Al-Sabah S. Role of bariatric surgery in reducing the risk of colorectal cancer: a meta-analysis. Br J Surg. 2020; 107:348–54.

53. Taube M, Peltonen M, Sjoholm K, Palmqvist R, Andersson-Assarsson JC, Jacobson P, et al. Long-term incidence of colorectal cancer after bariatric surgery or usual care in the Swedish Obese Subjects study. PLoS One. 2021; 16:e0248550.

54. Jin EH, Choi YJ, Lim JH, Shin CM, Han K, Lee DH. Alteration of metabolic syndrome is associated with the decreased risk of colorectal cancer. J Clin Med. 2023; 12:4889.

55. Sinicrope FA. Increasing incidence of early-onset colorectal cancer. N Engl J Med. 2022; 386:1547–58.

56. O'Sullivan DE, Hilsden RJ, Ruan Y, Forbes N, Heitman SJ, Brenner DR. The incidence of young-onset colorectal cancer in Canada continues to increase. Cancer Epidemiol. 2020; 69:101828.

57. Saad El Din K, Loree JM, Sayre EC, Gill S, Brown CJ, Dau H, et al. Trends in the epidemiology of young-onset colorectal cancer: a worldwide systematic review. BMC Cancer. 2020; 20:288.

58. O'Sullivan DE, Sutherland RL, Town S, Chow K, Fan J, Forbes N, et al. Risk factors for early-onset colorectal cancer: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2022; 20:1229–40.

59. US Preventive Services Task Force, Davidson KW, Barry MJ, Mangione CM, Cabana M, Caughey AB, et al. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA. 2021; 325:1965–77.

60. Sung H, Siegel RL, Rosenberg PS, Jemal A. Emerging cancer trends among young adults in the USA: analysis of a population-based cancer registry. Lancet Public Health. 2019; 4:e137–47.

61. Toydemir T, Ozgen G, Calikoglu I, Ersoy O, Yerdel MA. A comparative study evaluating the incidence of colorectal neoplasia(s) in candidates for bariatric surgery by screening colonoscopy, 40-49 versus 50-65 years old: a preliminary study. Obes Surg. 2019; 29:2430–5.

62. Breau G, Ellis U. Risk factors associated with young-onset colorectal adenomas and cancer: a systematic review and meta-analysis of observational research. Cancer Control. 2020; 27:1073274820976670.